Reporter brief
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Without reported results, findings or lack thereof on tirzepatide's effect on vasomotor symptoms cannot be established from this source.
- No conclusions about biological aging outcomes can be drawn, as no results are presented.
- A pilot design means findings would require confirmation in larger trials before generalizing to broader populations.
Study design and sample
Rct; Human.
post-menopausal women with obesity
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Oct 6, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.